摘要
目的 研究ｒａｓ、ｐ５３ 基因突变和蛋白表达及ＤＮＡ 倍体异常与尿路上皮肿瘤预后关系。 方法 应用ＰＣＲＳＳＣＰ和流式免疫荧光法检测５２ 例尿路上皮肿瘤Ｋｒａｓ 和ｐ５３ 基因突变及蛋白表达和ＤＮＡ 含量变化。 结果 Ｋｒａｓ、ｐ５３ 基因突变分别为５ 例（９ ．６ ％ ） 和２２ 例（４２ ．３ ％ ） ；ｒａｓ ｐ２１ 、ｐ５３ 蛋白阳性表达分别为３６ 例（６９ ．２ ％ ） 和３３ 例（６３ ．５ ％ ） ；异倍体和二倍体肿瘤分别为２２ 例（４２ ．３ ％ ） 和３０ 例（５７ ．７ ％ ） ；ＤＮＡ 倍体异常、ｐ５３ 基因突变及ｒａｓ ｐ２１ 和ｐ５３ 蛋白表达与肿瘤病理分级、分期及预后密切相关（ Ｐ＜ ０ ．０１） ；异倍体肿瘤其ｐ５３ 基因突变、ｒａｓ ｐ２１ 和ｐ５３ 蛋白表达率均明显高于二倍体肿瘤（ Ｐ＜ ０ ．０１） 。 结论 ＤＮＡ 倍体异常、ｐ５３ 基因突变及ｒａｓ ｐ２１ 和ｐ５３ 蛋白表达对尿路上皮肿瘤预后判断有重要意义。
Objective To study K ras、p53 gene mutation,ras p21 and p53 protein overexpression and DNA ploidy abnormality in urothelial tumors. Methods In 52 cases of urothelial tumors,K ras and p53 gene mutations were studied by means of polymerase chain reaction and single stranded conformation polymorphism.ras p21 and p53 overexpression and DNA content were studied by flow cytometry and cellular immunofluorescence technique. Results K ras mutation was observed in 9.6% of the cases and p53 mutation in 42.3%.The positive protein expression rates of ras p21 and p53 were 69.2% and 63.5% respectively.22 (42.3%) were aneuploidy tumors and 30 (57.7%) diploidy tumors.DNA ploidy abnormality,p53 gene mutation and the positive expression of ras p21 and p53 proteins increased well with the rise of tumor grade and stage denoting a bad prognosis ( P <0.01).In aneuploidy tumors,p53 gene mutation and ras p21,p53 protein expression were higher than those in diploidy tumors ( P <0.01). Conclusions DNA ploidy abnormality,p53 gene mutation and ras p21,p53 protein overexpression might serve as markers for the prognosis of urothelial tumors.
出处
《中华泌尿外科杂志》
CAS
CSCD
北大核心
1999年第10期598-601,共4页
Chinese Journal of Urology
